COMPARISON OF CYTOLOGY AND CERVICOGRAPHY IN SCREENING A HIGH-RISK AUSTRALIAN POPULATION FOR CERVICAL HUMAN PAPILLOMAVIRUS AND CERVICAL INTRAEPITHELIAL NEOPLASIA

被引:8
|
作者
MCKINNON, KJ [1 ]
FORD, RM [1 ]
HUNTER, JC [1 ]
机构
[1] SYDNEY HOSP,SYDNEY STD CTR,SYDNEY,NSW 2000,AUSTRALIA
关键词
D O I
10.1111/j.1479-828X.1993.tb02387.x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Two different screening methods, the Papanicolaou (Pap) smear and cervigram were compared in screening 245 Sydney women over a 6-month period in 1988 at a city sexually transmitted diseases (STD) centre, for cervical human papillomavirus (HPV), cervical intraepithelial neoplasia (CIN) and cervical cancer. The Pap smear through the identification of cytologically abnormal cells correctly detected 54% of cases of histologically proven CIN and 39.2% of cases of HPV. The cervigram through the identification of acetowhite epithelium and/or abnormal vessels on the cervix correctly detected 64% of cases of histologically proven CIN and 70.6% of cases of HPV. However, when both tests were used together, 92% of CIN lesions and 82.4% of HPV lesions were correctly identified. Histology of a colposcopically directed biopsy was used as the 'gold standard'. The sensitivity and specificity of the Pap smear after correction for verification bias was 46% and 78% respectively, and for the cervigram was 49% and 60% respectively. Hence neither screening test appears adequate on its own, at least in an STD population.
引用
收藏
页码:176 / 179
页数:4
相关论文
共 50 条
  • [31] Prevalence of high-risk human papillomavirus types in Mexican women with cervical intraepithelial neoplasia and invasive carcinoma
    López-Revilla R.
    Martínez-Contreras L.A.
    Sánchez-Garza M.
    Infectious Agents and Cancer, 3 (1)
  • [32] The High-Risk Human Papillomavirus Type Influences the Tissue Microenvironment in Cervical Intraepithelial Neoplasia Grade 2
    Saito, Mayumi
    Rajesh, Aarthi
    Innes, Carrie
    van der Griend, Rachael
    Fitzgerald, Peter
    Simcock, Bryony
    Sykes, Peter
    Hibma, Merilyn
    VIRUSES-BASEL, 2023, 15 (09):
  • [33] High-risk Human Papillomavirus Reduces the Expression of MicroRNA-218 in Women with Cervical Intraepithelial Neoplasia
    Li, Y.
    Liu, J.
    Yuan, C.
    Cui, B.
    Zou, X.
    Qiao, Y.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2010, 38 (05) : 1730 - 1736
  • [34] Human papillomavirus types in cervical infection and cervical intraepithelial neoplasia
    Stefanescu, C. D.
    Calistru, P. I.
    Gherlan, G. S.
    Gherlan, I.
    VIRCHOWS ARCHIV, 2015, 467 : S113 - S114
  • [35] High-risk human papillomavirus testing for monitoring patients treated for high-grade cervical intraepithelial neoplasia
    Jeong, Nan Hee
    Lee, Nak Woo
    Kim, Hai Joong
    Kim, Tak
    Lee, Kyu Wan
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2009, 35 (04) : 706 - 711
  • [36] High-Risk Human Papillomavirus Identification in Precancerous Cervical Intraepithelial Lesions
    Zheng, Ruifang
    Heller, Debra S.
    JOURNAL OF LOWER GENITAL TRACT DISEASE, 2020, 24 (02) : 197 - 201
  • [37] Human papillomavirus deoxyribonucleic acid testing in screening of high grade cervical intraepithelial neoplasia
    Zdenek, H
    Lukac, J
    Jabor, A
    Chvalova, M
    Voracek, J
    Brozkova, H
    SAUDI MEDICAL JOURNAL, 1999, 20 (11) : 861 - 864
  • [38] The vaginal microbiota, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia: results from a population-based study
    McKee, K. S.
    Carter, K. A.
    Bassis, C.
    Young, V.
    Reed, B.
    Harper, D.
    Ruffin, M. T.
    Bell, J.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2019, 221 (06) : 668 - 668
  • [39] High-risk Human Papillomavirus Testing for Cervical Cancer Screening
    Totten, Stephanie P. S.
    Romero, Joan Miguel
    JAMA ONCOLOGY, 2021, 7 (07) : 1066 - 1067
  • [40] Predicting cervical intraepithelial neoplasia and determining the follow-up period in high-risk human papillomavirus patients
    Gong, Ling
    Tang, Yingxuan
    Xie, Hua
    Zhang, Lu
    Sun, Yali
    FRONTIERS IN ONCOLOGY, 2024, 13